0000950170-24-077518.txt : 20240625
0000950170-24-077518.hdr.sgml : 20240625
20240625200002
ACCESSION NUMBER: 0000950170-24-077518
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240621
FILED AS OF DATE: 20240625
DATE AS OF CHANGE: 20240625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arif Bilal
CENTRAL INDEX KEY: 0001959750
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 241070347
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
ownership.xml
4
X0508
4
2024-06-21
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001959750
Arif Bilal
215 FIRST STREET
CAMBRIDGE
MA
02129
false
true
false
false
Chief Tech Ops Officer
true
Common Stock
2024-06-21
4
M
false
6250
A
31472.00
D
Common Stock
2024-06-24
4
F
false
2352
164.64
D
29120.00
D
Common Stock
2024-06-24
4
S
false
5580
162.31
D
23540.00
D
Common Stock
2024-06-24
4
S
false
1055
163.83
D
22485.00
D
Common Stock
2024-06-24
4
S
false
300
164.61
D
22185.00
D
Common Stock
2024-06-24
4
S
false
700
166.10
D
21485.00
D
Common Stock
2024-06-24
4
S
false
224
167.13
D
21261.00
D
Common Stock
2024-06-25
4
S
false
3898
163.23
D
17363.00
D
Performance Stock Units
2024-06-21
4
A
false
6250
0
A
Common Stock
6250
6250
D
Performance Stock Units
2024-06-21
4
M
false
6250
0
D
Common Stock
6250
0
D
Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.
Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.25 to $163.21, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.35 to $164.18, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.38 to $164.91, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.69 to $166.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.91 to $167.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Ryan Brown as Attorney-in-Fact for Bilal Arif
2024-06-25